Cutia Therapeutics Unveils Successful Acne Treatment Trial

Cutia Therapeutics (HK:2487) has released an update.

Cutia Therapeutics has presented positive results from their Phase III clinical trial of CU-10201, a new topical acne treatment, at the 13th Asian Dermatology Congress. The treatment showed significant improvement in patients with moderate to severe acne over 12 weeks, with no serious adverse events reported. CU-10201 has received priority review designation and an accepted New Drug Application in the PRC, signaling a potential breakthrough in acne therapy.

For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.